-
.
- Guggenheim begins insurance coverage on Chinook Therapies Inc KDNY with a Buy ranking as well as a $43 rate target, being ‘favorable’ on the immunoglobulin A nephropathy (IgAN) market.
- .
- .
- Travere Therapies Inc TVTX is leading an amazing course for endothelin receptor villains (Ages) in IgAN as well as FSGS, yet the expert thinks atrasentan’s extra considerable security data source might permit it to have a much less limiting rapid eye movement program. .
- .
- KDNY shares are up 4.67% at $22.84 on the last check Wednesday. .
.(* )The expert is” favorable “on the enhanced passion, financial investment, as well as technology in the immunoglobulin A nephropathy, or IgAN, market as well as thinks Chinook is “well-positioned to gain from these fads.”
Atrasentan as well as BION-1301 have actually each revealed “remarkable very early information,” creates the expert, while their advantages still require to be shown in crucial tests.
Competing medication Filspari from
Guggenheim jobs both medications to make it to the marketplace as well as hold >>$ 1 billion yearly optimal sales possibility by 2030, expecting a 2025 atrasentan launch, with a 75% chance of success in IgAN as well as a 45% chances of success in focal segmental glomerulosclerosis (FSGS).
Rate Activity:
© 2023 Benzinga.com. Benzinga does not supply financial investment guidance. All legal rights scheduled.
